Phase 1 Hyperuricemia Clinical Trials
5 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
HyperuricemiaHypouricemia, Renal
Intelligem Therapeutics Australia Pty Ltd.60 enrolled6 locationsNCT06310967
Recruiting
Phase 1
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
Healthy VolunteersHyperuricemia
Novo Nordisk A/S60 enrolled2 locationsNCT06859073
Recruiting
Phase 1
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
GoutHyperuricemia
Shenyang Sunshine Pharmaceutical Co., LTD.60 enrolled1 locationNCT06629376
Completed
Phase 1
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers
Chronic goutHyperuricemia
Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc.50 enrolled1 locationACTRN12619000908134
Completed
Phase 1
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Rising Dose Study of AR882 in Healthy Adult Male Volunteers
Chronic goutHyperuricemia
Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc.72 enrolled1 locationACTRN12619000021178